Logo

MorphoSys Antibodies by Design and JPT Peptide Technologies to Co-Market Products and Services

Apr 18, 2005

NEW YORK, April 18 (GenomeWeb News) - MorphoSys' Antibodies by Design division and JPT Peptide Technologies of Germany will co-market their antibody and peptide products and services, the companies said today.

 

Under the agreement, Antibodies by Design, of Martinsried, and JPT, a subsidiary of Berlin-based Jerini, will offer each other's products and services to customers worldwide, except for Japan.

 

Antibodies by Design develops monoclonal antibodies, while JPT offer complementary peptide-based services and products.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.